A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies
Status:
Terminated
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 clinical trial designed to evaluate increasing durations of MLN8054 oral
dosing in patients with advanced malignancies. MLN8054 will be given once daily for 4 to 7
consecutive days per week for 2 to 3 weeks. Following the 2- to 3-week treatment period there
will be a 2 week recovery period.